An Experts' Forum in Tokyo and Singapore on DDR and PARP inhibition

Prof. Keiichi Fujiwara has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Abbvie, AstraZeneca, Clovis, Eisai, MSD, Ono, Pfizer and Takeda.

Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Artios Pharma Ltd.

Dr Shinji Ohno has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Chugai, Eisai, Eli Lilly, KyowaHakko, Kirin and Taiho

Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.

Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

An Experts’ Forum in Tokyo and Singapore on DDR and PARP inhibition

Prof. Keiichi Fujiwara

Prof. Simon Boulton

Dr Shinji Ohno

Dr Rebecca Dent

Prof. Charlie Gourley

Publication Date

Overview

Experts

Downloads

Learn about the role of PARP inhibitors in clinical practice and targeting DDR, including:

Mechanism of Action of PARP inhibition and targeting DDR

Clinical profile of PARP inhibitors and their benefit in ovarian and breast cancer

Appropriate patient selection for PARP inhibition

Future DDR and PARP inhibition

Prof. Keiichi Fujiwara Gynaecologic Oncologist Saitama Medical University International Medical Center Japan (JP)

Prof. Keiichi Fujiwara

Disclosures

Prof. Simon Boulton Senior Scientist Francis Crick Institute United Kingdom (GB)

Prof. Simon Boulton

Disclosures

Dr Shinji Ohno Medical Oncologist Cancer Institute Hospital of JFCR Japan (JP)

Dr Shinji Ohno

Disclosures

Dr Rebecca Dent Medical Oncologist National Cancer Center Singapore Singapore (SG)

Dr Rebecca Dent

Disclosures

Prof. Charlie Gourley Medical Oncologist CRUK Edinburgh Centre, Nicola Murray Centre for Ovarian Cancer Research United Kingdom (GB)

Prof. Charlie Gourley

Disclosures

Programme summary

Share this programme

I agree that this educational programme:

Other programmes of interest

Precision oncology in prostate and gastric cancer: tips for optimal genomic testing

Experts

Endorsed by

Episode

2

of 2

HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch

Experts

Endorsed by

Testing to treatment of BRAF-mutant metastatic NSCLC

Experts

Episode

1

of 2

HCC podcast series part 1: The use of IO in unresectable HCC

Experts

Endorsed by

The emerging role of artificial intelligence in precision oncology

Experts

BRAF-mutated CRC: from testing to treatment

Experts

Endorsed by